Evidence map›Paper›PMID 41312169›Full record

ArticleFrontiers in oncology2025

Case Report: Recognition and management of SMARCA4-deficient renal cell carcinoma.

Weibo Wang, Shuiping Yin, Dandan Xu, Supeng Tai, Xi Cheng, Yifan Chang, Yao Fu, Jun Zhou

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weibo Wang *Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Shuiping Yin *Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Dandan XuDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Supeng TaiDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Xi ChengDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yifan ChangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yao FuDepartment of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jun ZhouDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMARCA4-deficient tumors represent a highly aggressive subtype of malignancy defined by the loss of SMARCA4 expression, and are associated with rapid progression and poor prognosis. We report the first documented case of SMARCA4-deficient renal cell carcinoma (RCC) in an adult (pT3aN1M1, Stage IV), characterized by sarcomatoid and rhabdomyoblastic differentiation, aggressive clinical behavior, and resistance to standard systemic therapies. This case provides a comprehensive analysis of clinical, pathological, imaging, and genetic findings, offering insights to refine diagnostic, therapeutic, and preventive strategies for this rare malignancy.

Indexed as

germline mutationrenal cell carcinomarhabdomyoblastic differentiationsarcomatoid differentiationSMARCA4-deficient tumor

Identifiers

PMID41312169
PMCPMC12646913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.